Analyzing...
Loading company...
Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 18,971 full-time employees. The firm is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The firm has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The firm along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹27,958 Cr revenue.
COGS 26.2%, employees 16.4%.
“margins have expanded by 750 basis points year over year and 470 basis points quarter over quarter reaching 31.”
“full year EBITDA margins to be in the range of 25 to 26%, higher than our earlier guidance of 24 to 25%.”
“we should be, you know, close to between 275 to $300,000,000 per quarter to close over $1,000,000,000 as we have guided, in the past.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 23.8%▲ | 10.3% |
| ROCE | 28.4%▲ | 13.7% |
| Net Margin | 18.8%▲ | 7.6% |
| EBITDA Margin | 30.6%▲ | 15.4% |
| Debt To Equity | 0.26x▲ | 0.15x |
| Rev Growth 3yr | 19.3%▲ | 10.0% |
| EPS Growth 3yr | 131.1%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹27,958 Cr +23.1% | ₹22,708 Cr +13.5% | ₹20,011 Cr +20.2% | ₹16,642 Cr +1.4% | ₹16,405 Cr +8.2% | ₹15,163 Cr -1.4% | ₹15,375 Cr -6.1% | ₹16,369 Cr |
| Other Income | ₹424 Cr +116.8% | ₹196 Cr +63.0% | ₹120 Cr +63.8% | ₹73 Cr -48.2% | ₹142 Cr +4.0% | ₹136 Cr -71.8% | ₹484 Cr -32.1% | ₹713 Cr |
| Total Income | ₹28,382 Cr +23.9% | ₹22,904 Cr +13.8% | ₹20,131 Cr +20.4% | ₹16,715 Cr +1.0% | ₹16,547 Cr +8.2% | ₹15,299 Cr -3.5% | ₹15,859 Cr -7.2% | ₹17,082 Cr |
| COGS | ₹7,326 Cr +7.1% | ₹6,842 Cr +3.0% | ₹6,643 Cr -2.0% | ₹6,780 Cr +4.6% | ₹6,481 Cr +20.9% | ₹5,362 Cr -1.3% | ₹5,431 Cr -7.1% | ₹5,846 Cr |
| ₹20,952 Cr +10.9% | ₹18,889 Cr +6.7% | ₹17,709 Cr +10.7% | ₹15,999 Cr -10.7% | ₹17,920 Cr +31.5% | ₹13,624 Cr -5.1% | ₹14,353 Cr -5.7% | ₹15,229 Cr | |
| Profit Before Tax | ₹6,873 Cr +71.2% | ₹4,015 Cr +65.8% | ₹2,422 Cr +238.1% | ₹716 Cr ↑ Recovery | (₹1,373 Cr) ↓ Decline | ₹1,675 Cr +122.4% | ₹753 Cr -50.3% | ₹1,517 Cr |
| Exceptional Items | (₹558 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹752 Cr) -123.7% | (₹336 Cr) |
| ₹1,517 Cr +114.1% | ₹709 Cr +45.6% | ₹487 Cr +81.1% | ₹269 Cr +96.0% | ₹137 Cr -69.4% | ₹449 Cr -61.2% | ₹1,157 Cr +28.3% | ₹902 Cr | |
| Net Profit | ₹5,355 Cr +62.0% | ₹3,306 Cr +70.8% | ₹1,936 Cr +332.3% | ₹448 Cr ↑ Recovery | (₹1,509 Cr) ↓ Decline | ₹1,228 Cr ↑ Recovery | (₹270 Cr) ↓ Decline | ₹615 Cr |
| Profit (Owners) | ₹5,333 Cr +62.5% | ₹3,282 Cr +71.4% | ₹1,914 Cr +345.1% | ₹430 Cr ↑ Recovery | (₹1,528 Cr) ↓ Decline | ₹1,217 Cr ↑ Recovery | (₹272 Cr) ↓ Decline | ₹607 Cr |
| Minority Interest | ₹23 Cr -8.2% | ₹25 Cr +16.8% | ₹21 Cr +19.8% | ₹18 Cr -5.7% | ₹19 Cr +63.9% | ₹11 Cr +322.2% | ₹3 Cr -69.8% | ₹9 Cr |
| Other Comprehensive Income | ₹440 Cr ↑ Recovery | (₹91 Cr) ↓ Decline | ₹38 Cr +55.2% | ₹24 Cr -76.7% | ₹104 Cr -60.3% | ₹262 Cr ↑ Recovery | (₹608 Cr) -160.1% | (₹234 Cr) |
| EPS | ₹116.72 | ₹71.88 | ₹42.01 | ₹9.45 | (₹33.62) | ₹26.81 | (₹6.02) | ₹13.40 |
| Diluted Shares | ₹46 Cr | ₹46 Cr | ₹46 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Lupin Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Lupin Announces the Approval of Diazepam Injection, USP in the United States".
Lupin Limited has informed the Exchange regarding a press release dated July 31, 2026, titled "Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection".
Lupin Limited has informed the Exchange about Schedule of Earnings Call for Q1 FY27.
Lupin Limited has informed the Exchange about Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeuti...
Lupin Limited has informed the Exchange about copy of Newspaper Publication relating to Annual General Meeting and e-voting related information.
Lupin Limited has informed the Exchange regarding a press release dated July 14, 2026, titled "Lupin Recognized Among India s Best Employers in the Nation-Builders Category by Great Place To Work® Ind...
Lupin Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report of the Company for FY 2025-26'.
Lupin Limited has informed the Exchange regarding Notice of the Forty-Fourth Annual General Meeting of the Company and Integrated Report for FY 2025-26.
Lupin Limited has informed the Exchange that Record date for the purpose of Dividend is 17-Jul-2026.
Lupin Limited has informed the Exchange regarding Intimation of the Forty-Fourth Annual General Meeting to be held on Tuesday, August 04, 2026, at 04.00 p.m. (IST) through Video Conferencing/ Other Au...
Lupin Limited has informed the Exchange regarding Allotment of 2358 Shares.
Lupin Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Lupin Limited has informed the Exchange regarding a press release dated July 01, 2026, titled "Lupin Announces EMA Approval for NaMuscla® Expansion for Pediatric Indicationwith New Strengths".
Lupin Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain".
Lupin Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection".